whatshot

BHVN   $40.38  2.49% Market Closed After Close 40.79107 1.02%

Biohaven Ltd
show_chart Advanced Chart of BHVN
Last Events:

2023-08-09 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Signal in Stochastic changed from bullish reversal to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-08-06 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Trend pattern changed from расходящийся клин с наклоном вверх to канал.

2023-08-03 Trend pattern changed from канал to расходящийся клин с наклоном вверх.

2023-08-03 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-02 Trend pattern changed from расходящийся клин с наклоном вверх to канал.

Current temperature: 9.75
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 12
Target Price Mean 57.25
Mean unverified/preliminary 57.25 / 57.25
Target Price Low / High 52.00 / 66.00
Median / STD DEV 57.50 / 3.57
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell None
rsi Buy Buy Sell
macd None None None
stoch None None None
ma20 None ActivelyBuy Buy
ma50 None None None
ma100 Sell Sell None
Candlestick PatternSept. 16, 2024 After Bottom Gap Up - pattern is a made up of five candlesticks. Pattern appears on a downtrend. The pattern begins with a black candlestick. The next two days are also black days. The third day gaps down and opens below the close of the second day. The fifth day is a strong white with a gap above the previous day’s close. Considered to be a bullish reversal pattern.
ISIN VGG1110E1079
ceo Dr. Vladimir Coric M.D.
Website https://www.biohaven.com
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.